

Supplemental Table 1: Baseline characteristics of patients included and excluded in the analysis cohort based upon complete hemoglobin data (N=58,759)

	Hemoglobin measurements at baseline and six months (N = 40,410)	Hemoglobin measurement missing at baseline and/or six months (N = 18,349)	
	Value	Value	P *
Baseline hemoglobin, median (IQR)	11.1 (9.7, 12.5)	10.9 (9.5, 12.4)	
< 8.5 g/dL	4,158 (10.3%)	1,583 (12.2%)	
≥ 8.5 to ≤ 10 g/dL	8,121 (20.1%)	2,943 (22.6%)	
> 10 g/dL	28,131 (69.6%)	8,477 (65.2%)	
Hemoglobin at six months, median (IQR)	12.3 (11.2, 13.4)	12.3 (11.2, 13.4)	0.31++
< 8.5 g/dL	1,117 (2.8%)	62 (1.7%)	0.70**
≥ 8.5 to ≤ 10 g/dL	3,030 (7.5%)	307 (8.6%)	
> 10 g/dL	36,263 (89.7%)	3,193 (89.6%)	
Age, median years (IQR)	35 (30, 41)	34 (29, 40)	<0.01**
Male, %	14,992 (37.1%)	7,301 (39.8%)	<0.01**
BMI, median (IQR)	20 (18, 22)	20 (18, 22)	<0.01++
< 16.0 kg/m ²	2,539 (6.6%)	1,320 (8.1%)	<0.01**
16.0 – 16.99 kg/m ²	2,561 (6.7%)	1,239 (7.6%)	
17.0 – 18.49 kg/m ²	6,110 (15.9%)	2,635 (16.1%)	
≥ 18.5 kg/m ²	27,282 (70.9%)	11,154 (68.2%)	
Baseline CD4, median (IQR)	146.0 (80.0, 211.0)	140.0 (72.0, 210.0)	<0.01++
< 50	5,608 (14.1%)	2,712 (16.5%)	<0.01**
≥ 50 to < 200	22,744 (57.1%)	9,056 (55.2%)	
≥ 200 to < 350	9,926 (24.9%)	3,842 (23.4%)	
≥ 350	1,548 (3.9%)	796 (4.9%)	
WHO Stage			
Stage I or II	15,883 (39.5%)	6,462 (35.8%)	<0.01**
Stage III	21,653 (53.9%)	10,227 (56.7%)	
Stage IV	2,630 (6.5%)	1,349 (7.5%)	
Tuberculosis (active)	5,345 (13.2%)	2,548 (13.9%)	0.03**
Baseline Regimen Dispensed			
ZDV + 3TC + NVP	12,219 (30.3%)	5,406 (29.7%)	<0.01**
ZDV + 3TC + EFV	1,127 (2.8%)	444 (2.4%)	
D4T + 3TC + NVP	9,485 (23.5%)	5,548 (30.5%)	

D4T + 3TC + EFV	1,494 (3.7%)	746 (4.1%)	
TDF + FTC + NVP	6,449 (16.0%)	1,837 (10.1%)	
TDF + FTC + EFV	9,558 (23.7%)	4,234 (23.2%)	
Other	1,323 (3.3%)	622 (3.4%)	
Adherence at Six Months according to MPR, %			
≥ 95%	29,784 (73.7%)	11,609 (63.3%)	<0.01**
80 – 94%	7,185 (17.8%)	3,707 (20.2%)	
< 80%	3,441 (8.5%)	3,033 (16.5%)	

** Chi-square test; ++ Wilcoxon Rank Sum Test